Today: 23 May 2026
Intel stock price slides into the weekend — what INTC investors watch next week
1 February 2026
1 min read

Intel stock price slides into the weekend — what INTC investors watch next week

New York, Feb 1, 2026, 05:29 EST — Markets have shut down for the day.

  • Intel shares dropped 4.5% on Friday, closing at $46.47.
  • A recent filing revealed Vanguard owned an 8.11% stake as of Dec. 31.
  • This week, investors will digest a slew of U.S. economic data alongside key tech earnings reports.

Intel’s stock dipped 4.5% on Friday, ending at $46.47. The chipmaker continues to face volatility as investors prepare for a data-packed start to February.

This shift is significant since Intel’s stock lately reacts as much to broader economic shifts as to its own updates. Concerns over rising rates and political uncertainty in Washington can quickly rattle semiconductor stocks, with Intel standing out as one of the most volatile big-cap chipmakers in recent days.

Intel last month projected first-quarter revenue between $11.7 billion and $12.7 billion. The company also flagged non-GAAP earnings per share at $0.00, signaling a break-even adjusted profit. Supply constraints are expected early in the quarter, CEO Lip-Bu Tan emphasized growing confidence in CPUs’ role in the AI landscape. CFO David Zinsner added that available supply would hit its lowest point in Q1 before easing later.

A separate filing revealed more on the stock’s ownership. On Friday, The Vanguard Group disclosed via a Schedule 13G/A that it holds beneficial ownership of 404.5 million Intel shares, representing 8.11% of the class as of Dec. 31.

Monday kicks off with a key gauge of economic health: the Institute for Supply Management’s manufacturing PMI, set for release at 10:00 a.m. EST. This survey has a history of jolting rate forecasts and cyclical stocks almost immediately.

Friday’s jobs report is next up. The Bureau of Labor Statistics has the Employment Situation for January 2026 set for release on Feb. 6 at 8:30 a.m. This number could shake up expectations for the next move in interest rates.

Earnings will likely provide more clues. Traders are set to dissect reports from Alphabet and Amazon.com, looking for hints on cloud demand and AI investments — and whether this surge in spending is widespread or tightening.

Investors focused on Intel will watch closely for cues from competitors’ earnings. Advanced Micro Devices is set to release its numbers Tuesday, Feb. 3, after markets close, followed by Qualcomm on Wednesday, Feb. 4, also post-close.

A spotless week isn’t certain. Should rate concerns flare up again, or if investors start to doubt that Intel’s supply issues and margin pressures will ease soon, the stock could slide without any new company news. Meanwhile, rivals in PCs and data-center chips keep pressing forward.

Looking ahead, the immediate trigger is straightforward: Monday’s reopening trade leads into a stretch of megacap earnings midweek, capped off by Friday’s U.S. jobs report — a lineup that could easily transform a quiet weekend for Intel into a sudden, sharp shift.

Stock Market Today

  • UBS Boosts Jazz Pharma Stock Price Target to $307 Ahead of FDA Decision
    May 23, 2026, 2:29 PM EDT. UBS upgraded Jazz Pharmaceuticals (JAZZ) stock from neutral to buy, raising its price target by 63% to $307 from $188. This surge exceeds the prior consensus of $242 and follows strong Q1 results, with revenue up 19% year-over-year and oncology portfolio growth of 45%. The move anticipates FDA approval on August 25 of Zanidatamab (Ziihera) for HER2-positive gastroesophageal cancer, expected to generate peak sales of $3.1 billion. UBS projects 10% revenue and 11% earnings growth from 2026-2030, versus consensus of around 7% and 6%, and supports a valuation multiple increase from 7x to 10x earnings, reflecting confidence in sustainable growth. Key risks include FDA delays, slower oncology sales ramp, and underperformance of core franchises like Xywav and Epidiolex.

Latest articles

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

23 May 2026
AbbVie shares closed Friday at $215.70, up 0.56%, gaining 2.5% for the week. The company reported a positive European panel recommendation for MAVIRET in acute hepatitis C and released new oncology data ahead of the ASCO meeting. U.S. markets are closed Monday for Memorial Day, with trading set to resume Tuesday.
Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

23 May 2026
Coherent Corp. shares closed at $377.57 Friday, down 0.1% for the day and 1.3% below last week, underperforming the S&P 500 and Nasdaq ahead of the Memorial Day market closure. The company reported fiscal Q3 revenue of $1.81 billion, up 21% year-over-year, with strong demand in datacenter and communications. Nvidia invested $2 billion in March and signed a multi-year optics agreement. Coherent trades at 179 times trailing earnings.
Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

23 May 2026
Intuit will cut about 3,000 jobs, or 17% of its workforce, and close offices in Reno and Woodland Hills as it restructures to focus on artificial intelligence. The company expects $300 million to $340 million in charges, mostly in the fiscal fourth quarter. Intuit raised full-year revenue guidance but lowered its TurboTax outlook, citing pressure from low-cost AI tools. Shares last traded at $319.94 after a volatile week.
NS&I’s £3bn IT overhaul hits another reset as Premium Bonds giant weighs cutting legacy links
Previous Story

NS&I’s £3bn IT overhaul hits another reset as Premium Bonds giant weighs cutting legacy links

HBAN stock price: Huntington shares see volume spike as Cadence merger close date nears
Next Story

HBAN stock price: Huntington shares see volume spike as Cadence merger close date nears

Go toTop